RA Capital Sells Over $530K in Werewolf Therapeutics Shares, Reducing Stake to 7.5%
HOWL is trading near its 52-week low of $0.338 (4.8% above the low).
Summary
Major institutional investor RA Capital Management sold over $530,000 of Werewolf Therapeutics stock, reducing its ownership to 7.5% amidst the company's financial challenges and strategic review.
Key Events · Ownership and Investor Activity · HOWL
-
Significant Stake Reduction
RA Capital Management, L.P. and its affiliates sold 1,484,396 shares of Werewolf Therapeutics common stock between June 16 and June 22, 2026.
-
Over $530K in Sales
The total value of these open market sales amounted to approximately $531,710, executed at average prices between $0.35 and $0.37 per share.
-
Ownership Reduced to 7.5%
Following these transactions, RA Capital's beneficial ownership in Werewolf Therapeutics has decreased to 3,654,307 shares, representing 7.5% of the outstanding common stock.
-
Ongoing Institutional Distribution
This sale continues a pattern of institutional investors reducing their positions, occurring while the company explores strategic alternatives and faces "going concern" doubts.
Analysis · HOWL · Life Sciences
RA Capital Management, a major institutional investor, has significantly reduced its stake in Werewolf Therapeutics by selling over $530,000 worth of shares in open market transactions. This ongoing distribution by a key investor, representing nearly 3% of the company's market cap and almost 29% of their prior holdings, adds to concerns given the company's previously disclosed "going concern" issues and exploration of strategic alternatives. The sales occurred while the stock trades near its 52-week low.
At the time of this filing, HOWL was trading at $0.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18M. The 52-week trading range was $0.34 to $2.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.